A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. - Koyama T; Yonemori K; Sato J; Katsuya Y; Okada M; Yoshida T; Okano F; Yamamoto N (Investigational new drugs, 2026)